Literature DB >> 33933600

Extracellular vesicles in renal inflammatory and infectious diseases.

Diana Karpman1, Ashmita Tontanahal2.   

Abstract

Extracellular vesicles can mediate cell-to-cell communication, or relieve the parent cell of harmful substances, in order to maintain cellular integrity. The content of extracellular vesicles includes miRNAs, mRNAs, growth factors, complement factors, cytokines, chemokines and receptors. These may contribute to inflammatory and infectious diseases by the exposure or transfer of potent effectors that induce vascular inflammation by leukocyte recruitment and thrombosis. Furthermore, vesicles release cytokines and induce their release from cells. Extracellular vesicles possess immune modulatory and anti-microbial properties, and induce receptor signaling in the recipient cell, not least by the transfer of pro-inflammatory receptors. Additionally, the vesicles may carry virulence factors systemically. Extracellular vesicles in blood and urine can contribute to the development of kidney diseases or exhibit protective effects. In this review we will describe the role of EVs in inflammation, thrombosis, immune modulation, angiogenesis, oxidative stress, renal tubular regeneration and infection. Furthermore, we will delineate their contribution to renal ischemia/reperfusion, vasculitis, glomerulonephritis, lupus nephritis, thrombotic microangiopathies, IgA nephropathy, acute kidney injury, urinary tract infections and renal transplantation. Due to their content of miRNAs and growth factors, or when loaded with nephroprotective modulators, extracellular vesicles have the potential to be used as therapeutics for renal regeneration.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extracellular vesicles; Inflammation; Kidney; Shiga toxin, Complement; Thrombosis; Vasculitis

Mesh:

Year:  2021        PMID: 33933600     DOI: 10.1016/j.freeradbiomed.2021.04.032

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  3 in total

1.  Novel Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors for Treating Diabetic Complications, Ocular Diseases and Edema-Associated Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-11-24       Impact factor: 4.345

2.  Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-03-04       Impact factor: 4.632

3.  Proteinuria is accompanied by intratubular complement activation and apical membrane deposition of C3dg and C5b-9 in kidney transplant recipients.

Authors:  Gustaf L Isaksson; Marie B Nielsen; Gitte R Hinrichs; Nicoline V Krogstrup; Rikke Zachar; Heidi Stubmark; Per Svenningsen; Kirsten Madsen; Claus Bistrup; Bente Jespersen; Henrik Birn; Yaseelan Palarasah; Boye L Jensen
Journal:  Am J Physiol Renal Physiol       Date:  2021-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.